Clinical Trials

Title   An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma
Description   The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic platinum-refractory cervical cancer treated with either REGN2810 or investigator's choice (IC) chemotherapy.
IRB Number   1100574-1
Treatment   Oncology - Cervical Cancer
Status   Active
Start Date   08/11/2017
Principal Name   Rodney Rocconi, MD
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us